Heparin-induced thrombocytopenia: Molecular pathogenesis

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 448-456

  Visentin, Gian Paolo ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; IMMUNOGLOBULIN G ANTIBODY; THROMBOCYTE FACTOR 4; THROMBOCYTE RECEPTOR;

CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0032723867     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615865     Document Type: Conference Paper

References (62)

1. Deykin D. Current status of anticoagulant therapy. Am J Med. 1982;72:661.
2. Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Low-Molecular-Weight-Heparins In Prophylaxis and Therapy of Thromboembolic Diseases. Bounameaux H, ed. New York: Marcel Dekker, Inc.; 1994:75-127.
3. Edson JR. Heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:355-356.
4. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg. 1958;76:219-227.
5. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia. Warkentin TE, Greinacher A, eds. New York: Marcel Dekker, Inc.; In press.
6. Husheksky WJ. Subcutaneous heparin-induced thrombocytopenia. Arch Intern Med. 1978;138:1489-1491.
7. Heeger PS, Backstrom JR. Heparin flushes and thrombocytopenia. Ann Intern Med. 1986;105:143.
8. Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Arch Intern Med. 1989;149:2285-2287.
9. Lecompte T. Thrombocytopenia associated with low-molecular-weight heparin (letter). Lancet. 1991;338:1217.
10. Tardy B. Thrombocytopenia associated with low-molecular-weight heparin (letter). Lancet. 1991;338:1217.
11. Tardy-Poncet B, Tardy B, Grelac F, Reynaud J, Mismetti P, Bertrand JC, Guyotat D. Pentosan polysulfate-induced thrombocytopenia and thrombosis. [Review]. Am J Haematol. 1994;45:252-257.
12. Magnani HN. Heparin-induced thrombocytopenia (HITP): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost. 1993;70:554-561.
13. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG synthesis that induces thromboxane synthesis and platelet aggregation. Lancet. 1982;2:1246-1248.
14. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb. 1991;10:1-34.
15. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72:925-930.
16. Greinacher A, Michels I, Mueller-Eckert C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost. 1992;67:545-549.
17. Green D, Harris K, Reynolds N, Roberts M, and Patterson R. Heparin immune thrombocytopenia: evidence for heparin-platelet complex as the antigenic determinate. J Lab Clin Med. 1978;91:167-175.
18. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316:581-589.
19. Foresti V, Guareschi G, Pediconi A, Scolari N, Vismara A, Confalonieri F. Platelet aggregating IgG without antibodies to endothelial cells in a case of heparin-induced thrombocytopenia with thrombotic complication. Hematologica. 1988;73:125-127.
20. Amiral J, Bridey, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia (letter). Thromb Haemost. 1992;68:95-96.
21. Visentin GP, Ford SE, Scott PJ, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
22. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
23. Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and Platelet factor 4. Blood. 1994;83:3232-3239.
24. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med. 1996;128:376-383.
25. Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol. 1997;54:196-201.
26. Amiral J, Bridey F, Wolf M. Antibodies to macromolecular platelet factor 4 heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost. 1995;73:21-28.
27. 14C-Serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995;104:648-654.
28. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. [Review]. N Engl J Med. 1998;338:436-445.
29. Poncz M, Surrey S, LaRocco P, Weiss MJ, Rappaport EF, Conway TM, Schwartz E. Cloning and characterization of platelet factor 4 cDNA derived from a human erythroleukemic cell line. Blood. 1987;69:219-223.
30. Zhang X, Chen L, Bancroft DP, Lai CK, Maione TE. Crystal Structure of Recombinant Human Platelet Factor 4. Biochemistry. 1994;33:8361-366.
31. Loscalzo J, Melnick B, Handin RI. The interaction of platelet factor 4 and glycosaminoglycans. Arch Biochem Biophys. 1985;240:446-455.
32. Maccarana M, Linbahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology. 1993;3:271-277.
33. Mayo KH, Ilyina E, Roongta V, Dundas M, Joseph J, Lai CK, Maione T, Daly TJ. Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding. Biochem J. 1995;312:357-365.
34. Höök M, Kjellén L, Johansson S, Robinson J. Cell surface glycosaminoglycans. Annu Rev Biochem. 1984;53:847-856.
35. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74:886-892.
36. Visentin GP, Moghaddam M, Aster RH. Antibodies associated with heparin-induced thrombo-cytopenia/thrombosis (HITP) recognize sites on platelet factor 4 (PF4) induced by the binding of linear polyanionic compounds (abstract). Thromb Haemost. 1997;(Suppl.):362.
37. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematology. 1996;95:161-167.
38. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis (HITT) recognize diverse epitopes on heparin: PF4 complexes. Blood. 1998;91:916-22.
39. St. Charles R, Walz DA, Edwards BFP. The 3-dimensional structure of bovine platelet factor 4 at 3.0 A resolution. J Biol Chem. 1989;264:2092-2099.
40. Mayo KH, Roongta V, Ilyina E, Milius R, Barker S, Quinlan C, La Rosa G, Daly TJ. NMR solution structure of the 32-kDa platelet factor 4 ELR-motif N-terminal chimera: a symmetric tetramer. Biochemistry. 1995;34:11399-11409.
41. Stuckey JA, St. Charles R, Edwards DFP. A model of the platelet factor 4 complex with heparin. Proteins. 1992;14:277-287.
42. Talpas CJ, Walz DA, Lee L. H-NMR studies of bovine platelet factor 4: histidine assignments and interactions with heparin. Biochimica Biophysica Acta. 1991;1078:208-218.
43. Stringer SE, Gallagher JT. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem. 1997;272:20508-20514.
44. Nieduszynski I. General physical properties of heparin. In Heparin: Chemical and Biological Properties, Clinical Applications. DA Lane and U Lindahl, eds., Boca Raton, FL: CRC Press, Inc.; 1989:51-63.
45. Amiral J, Marfang-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, Vissac AM, Fressinaud E, Poncz M, Meyer D. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood. 1996;88:410-416.
46. Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu, WY, Arepally G, Shoenfeld Y, Kieber-Emmons T, Cines DB, Poncz M. Defining an antigenic epitopes on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood. 1998;92:3250-3259.
47. Doit T, Greenberg SM, Rosenberg RD. Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation. Mol Cell Biol. 1987;7:898-904.
48. Visentin GP, Aster RH, Geoffrey RA. Identification of critical amino acids in human platelet factor 4 (PF4)-heparin complex required for antibody recognition in heparin-induced thrombocytopenia/thrombosis (HITP) (abstract). Thromb Haemost. 1997;(suppl.):362.
49. Amiral J, Wolf M, Fischer AM, Boyer-Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol. 1996;92:954-959.
50. Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood. 1997;89:370-375.
51. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia. Diagnosis, natural history, and treatment options. [Review]. Postgrad Med J. 1998;103:169-171,175-178.
52. Maslanka K, Piatek T, Gorski J, Yassai M, Gorski J. Molecular analysis of T cell repertoires. Spectratypes generated by multiplex polymerase chain reaction and evaluated by radioactivity or fluorescence. Hum Immunol. 1995;44: 28-34.
53. Cochet M, Pannetier C, Regnault A, Darche S, Leclerc C, Kourilsky P. Molecular detection and in vivo analysis of the specific T cell response to a protein antigen. Eur J Immunol. 1992;22:2639-2647.
54. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA. 1993;90:4319-4323.
55. Maslanka K, Yassai M, Gorski J. Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. J Clin Invest. 1996;98:1802-1808.
56. LaRoque R, Robinson MA. Diversity of the human T cell receptor beta chain. [Review]. Human Immunology. 1996;48:3-11.
57. De Palma R, Gorski J, Aster RH, Visentin GP. The immune response in heparin-induced thrombocytopenia/thrombosis (HITP): Preferential use of the VB11 family of the T cell receptor (TCR) repertoire (abstract). Blood. 1995;86 (suppl.):537a.
58. Bacsi S, De Palma R, Visentin GP, Gorski J, Aster RH. Complexes of heparin and platelet factor 4 (PF4) drive the T cell receptor (TCR) repertoire in cultured PBMCs from heparin-induced Thrombocytopenia/thrombosis (HITP) patients (abstract). Blood. 1996;88(Suppl.):516a.
59. Bacsi S, Geoffrey R, Gorksi J, Aster R. Antigen-specific expansion of T cell clonotypes in heparin-induced thrombocytopenia/thrombosis (HITT) patient cultured T cells (abstract). Blood. 1997;90:403a.
60. Greinacher A, Mueller-Eckhardt G. Heparin-associated thrombocytopenia: no association of immune response with HLA. Vox Sanguinis. 1993;65:151-153.
61. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. [Review]. Thromb Haemost. 1998;79:1-7.
62. Marcum JA, Rosenberg RD. The biochemistry, cell biology, and pathophysiology of anticoagulantly active heparin-like molecules of the vessel wall. In Heparin: Chemical and Biological Properties Clinical Applications. D.A. Lane and U. Lindal, eds. Boca Raton, FL: CRC Press, Inc.; 1989:275-294.